Cover Image

HARDBACK
$52.95



View/Hide Left Panel

Table A24–1 Incidence Rate for Noninvasive and Invasive Group A Streptococcus Infections

Age Groups

Population

Incidence Rates (per 100,000)

Cases

NONINVASIVE INFECTIONS

<1

3,963,000

1,009.34

40,000

1–4

16,219,000

2,466.24

400,000

5–14

38,056,000

8,408.66

3,200,000

15–24

36,263,000

992.75

360,000

25–34

41,670,000

0.00

0

35–44

42,149,000

0.00

0

45–54

30,224,000

0.00

0

55–64

21,241,000

0.00

0

65–74

18,964,000

0.00

0

75–84

11,088,000

0.00

0

85+

3,598,000

0.00

0

Total

263,435,000

1,518.4

4,000,000

INVASIVE INFECTIONS

<1

3,963,000

5.69

226

1–4

16,219,000

5.69

924

5–14

38,056,000

5.69

2,167

15–24

36,263,000

5.69

2,065

25–34

41,670,000

5.69

2,373

35–44

42,149,000

5.69

2,400

45–54

30,224,000

5.69

1,721

55–64

21,241,000

5.69

1,209

65–74

18,964,000

5.69

1,080

75–84

11,088,000

5.69

631

85+

3,598,000

5.69

205

Total

263,435,000

5.69

15,000

For the purposes of this report, the committee assumed that invasive GAS disease manifests as necrotizing fasciitis (with and without lifetime sequelae) in 10% of cases and toxic shock (lasting 15 days and associated with HUIs of .16 during hospitalization and .58 following hospitalization) for 10% of cases. 80% of the invasive forms of the disease are associated with 2 weeks of illness and HUIs of .62 and .73 for the time spent inpatient and outpatient, respectively. See Table A24–2.

COST INCURRED BY DISEASE

Table A24–3 summarizes the health care costs incurred by GAS infections. For the purposes of the calculations in this report, it was assumed that all pa-



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement